The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of SGN-ALPV in Advanced Solid Tumors
Official Title: A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
Study ID: NCT05229900
Brief Summary: This study will test the safety of a drug called SGN-ALPV in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have three parts. Parts A and B of the study will find out how much SGN-ALPV should be given to participants. Part C will use the dose and schedule found in Parts A and B to find out how safe SGN-ALPV is and if it works to treat solid tumor cancers.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Women's Cancer Care, Fresno, California, United States
Yale Cancer Center, New Haven, Connecticut, United States
Florida Cancer Specialists - Lake Nona, Wellington, Florida, United States
START Midwest, Grand Rapids, Michigan, United States
Oklahoma University at Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
START Mountain Region, West Valley City, Utah, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
START Madrid-CIOCC_Hospital HM Sanchinarro, Madrid, Other, Spain
Karolinska University Hospital, Stockholm, Other, Sweden
The Royal Marsden NHS Foundation Trust (RM), London, Other, United Kingdom
Sarah Cannon Research Institute UK, London, Other, United Kingdom
Name: Suzanne McGoldrick, MD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR